My ePortfolio Register   

Preemptively treating patients most at risk of progression to myeloma

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 01.11.16
Views: 996

Prof Maria-Victoria Mateos - University Hospital of Salamanca, Salamanca, Spain

Prof Mateos talks to ecancertv at ICMM 2016 about the use of monoclonal gammopathy in early-stage pre-malignant disorders.

Unfortunately, she says, certain patients will see their disorder evolve into active myeloma disease.

She says it is important to predict better which patients are most at risk so they can be treated preemptively, possibly with lenalidomide and dexamethasone.

For more on this, watch the interview with Dr Van De Donk.

ecancer's filming at ICMM 2016 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content

Related videos

follow us



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence